

YAZIDA SIRAYLA KULLANILAN KAYNAKLAR

1. Metintas M, Gibbs AR, Harmancı E, et al. Malignant localized fibrous tumor of the pleura occurring in a person environmentally exposed to tremolite asbestos. *Respiration* 1997;64:236-239.
2. Rusch V, Saltz L, Venkatraman E, et al. A phase II trial of pleurectomy/decortication followed by intrapleural and systemic chemotherapy for malignant pleural mesothelioma. *J Clin Oncol* 1994;12:1156-1163.
3. Metintas M, Özdemir N, Hillerdal G, et al. Environmental asbestos exposure and malignant pleural mesothelioma. *Respir Med* 1999; 93: 349-55.
4. Wagner JC, Berry G, Pooley FD. Mesotheliomas and asbestos type in asbestos textile workers: a study of lung contents. *Br Med J* 1982;285:603-606.
5. Aisner J. Current approach to malignant mesothelioma of the pleura. *Chest* 1995;107:332S-344S.
6. Baris B, Demir AU, Shehu V, et al. Environmental fibrous zeolite (erionite) exposure and malignant tumors other than mesothelioma. *J Environ Path Tox Oncol* 1996;15:183-189.
7. Suzuki Y, Koyama N. Malignant mesothelioma induced by asbestos and zeolite in the mouse peritoneal cavity. *Environ Res* 1984;35:277-292.
8. Poole A, Brown RJ, Turwer CJ, et al. In vitro genotoxic activities of fibrous erionite. *Br J Cancer* 1983;47:697-705.
9. Maltoni C, Minardi F, Morisi L. Pleural mesotheliomas in Sprague-Dawley rats by erionite: first experimental evidence. *Environ Res* 1982;29:238-244.
10. Ozesmi M, Patıroglu T, Hillerdal G, et al. Peritoneal mesothelioma and malignant lymphoma in mice caused by fibrous zeolite. *Br J Ind Med* 1985;42:746-749.
11. Metintas S, Metintas M, Ucgun I, Oner U. Malignant mesothelioma due to environmental exposure to asbestos. *Chest* 2002; 122:2224-2229.
12. Hubbard R. The aetiology of mesothelioma: are risk factors other than asbestos exposure important ? *Thorax* 1997;52:496-497.
13. Emri S, Kocagöz T, Olut A, et al. Simian virus 40 is not a cofactor in the pathogenesis of environmentally in malignant pleural mesothelioma in Turkey. *Anticancer Res* 2000;20:891-894.
14. Hirvonen A, Mattson K, Karjalainen A, et al. Simian virus 40 (SV40)-like DNA sequences not detectable in Finnish mesothelioma patients not exposed to SV40-contaminated polio vaccines. *Mol Carcinog* 1999;26:93-99.
15. Mayall FG, Jacobson G, Wilkins R. Mutations of p53 gene and SV40 sequences in asbestos associated and non-asbestos-associated mesotheliomas. *J Clin Pathol* 1999;52:291-293.
16. Stenton SC. Asbestos, Simian virus 40 and malignant mesothelioma. *Thorax* 1997;52 (Suppl) 3:552-557.
17. Carbone M, Pass H, Rizzlo P, et al. Simian virus 40-like DNA sequences in human pleural mesothelioma. *Oncogene* 1994;9:1781-1790.
18. Hillerdal G. Mesothelioma: cases associated with non-occupational and low dose exposures. *Occup Environ Med* 1999;56:505-513.

19. Pisani RJ, Colby TV, Williams DE. Malignant mesothelioma of the pleura. *Mayo Clin Proc* 1988; 63: 1234-1244.
20. Boutin C, Schlessler M, Frenay C, Astoul P. Malignant pleural mesothelioma. *Eur Respir J* 1998;12:972-981.
21. Wagner JC. Diffuse pleural mesothelioma and asbestos exposure in the North-West Cape Province. *Br J Ind Med* 1960;17:260-271.
22. Yazicioglu S, Ilcayto R, Balci K, Sayli BS, Yorulmaz B. Pleural calcification, pleural mesotheliomas and bronchial cancers caused by tremolite dust. *Thorax* 1980; 35: 564 - 569.
23. Light RW. Tumors of the pleura. In: Murray JF, Nadel JA, eds. *Textbook of respiratory medicine*, vol 2. Philadelphia: Saunders, 1994: 2222-2230.
24. Metintas M, Hillerdal G, Metintas S. Malignant mesothelioma due to environmental exposure to erionite: follow-up of a Turkish emigrant cohort. *Eur Respir J* 1999;13:523-526.
25. Boring CC, Squires TS, Tong T. *Cancer statistics, 1993*. *Cancer* 1993;43:7-26.
26. Spirtas R, Beebe GW, Connelly RR, et al. Recent trends in mesothelioma incidence of the United States. *Am J Ind Med* 1986;9: 397-407.
27. Connelly RR, Spirtas R, Myers MH, et al. Demographic patterns for mesothelioma in the United States. *J Natl Cancer Inst* 1987;78:1053-1060.
28. Letourneux M, Galateau A, Legendre C, et al. Malignant mesotheliomas diagnosed in Lower Normandy between 1980 and 1990. *Eur Respir Rev* 1993;3:87-88.
29. Armstrong BK, De Klerk NH, Musk AW, Hobbs MST. Mortality in miners and millers of crocidolite in Western Australia. *Br J Ind Med* 1988; 45: 5-13.
30. Rogers A, Nevill M. Occupational and environmental mesotheliomas due to crocidolite mining activities in Wittenoom, Western Australia. *Scand J Work Environ Health* 1995; 21: 259-64.
31. Selcuk ZT, Emri S, Sahin A, et al. Malignant mesothelioma and erionite exposure. *Eur Respir J* 1999;14:480-481.
32. Isik R, Metintas M, Gibbs AR, et al. p53, p21 and metallothionein immunoreactivities in patients with malignant pleural mesothelioma: correlations with the epidemiological features and prognosis of mesotheliomas with environmental asbestos exposure. *Respir Med* 2001;95:588-593.
33. Fidaner C, Eser SY, Parkin DM. Incidence in Izmir in 1993-1994. First results from İzmir Cancer Registry. *Eur J Cancer*. 2001; 37: 83-92.
34. Baris YI. Asbestos and erionite related chest diseases. Ankara: Semih, 1987: 8-139.
35. Selcuk ZT, Coplu L, Emri S, et al. Malignant pleural mesothelioma due to environmental mineral fiber exposure in Turkey: Analysis of 135 cases. *Chest* 1992; 102: 790-96.
36. Tammilehto L, Maasilta P, Kostianen S, et al. Diagnosis and prognostic factors in malignant pleural mesothelioma: a retrospective analysis of sixty-five patients. *Respiration* 1992; 59: 129-135.
37. Qua JC, Rao UNM, Takita H. Malignant pleural mesothelioma: a clinicopathological study. *J Surg Oncol* 1993; 54: 47-50.
38. Dumortier P, Coplu L, Maertelaer V de, et al. Assessment of environmental asbestos exposure in Turkey by bronchoalveolar lavage. *Am J Respir Crit Care Med* 1998; 158: 1815-24.

39. Greenberg GN, Darcoy JD. Occupational and environmental exposure to asbestos. In: Roggli VL, Greenberg SD, Proff PC (eds). Pathology of asbestos-associated diseases. Boston: Little, Brown and Company, 1992; 19-37.
40. Coplu L, Dumortier P, Demir AU, et al. An epidemiological study in an Anatolian village in Turkey environmentally exposed to tremolite asbestos. *J Environ Pathol Toxic Oncol* 1996; 15: 177-82.
41. Peto J, Hodgson JT, Matthews FE, Jones JR. Continuing increase in mesothelioma mortality in Britain. *Lancet* 1995;345:535-539.
42. McDonald JC, McDonald AD. The epidemiology of mesothelioma in historical context. *Eur Respir J* 1996;9:1932-1942.
43. Senyigit A, Babayigit C, Gokirmak M, et al. Incidence of malignant pleural mesothelioma due to environmental asbestos fiber exposure in the southeast of Turkey. *Respiration* 2000;67:610-614.
44. Boutin C, Dumortier P, Rey F, et al. Black spots concentrate oncogenic fibers in the parietal pleura. Thoracoscopic and mineralogic study. *Am Respir Crit Care Med* 1996;153:444-449.
45. Moyer VD, Cistulli CA, Vaslet CA, Kane AB. Oxygen radicals and asbestos carcinogenesis. *Environ Health Perspect* 1994;102 (Suppl):131-136.
46. Bielefeldt-Ohmann H, Jarnick AG, Fitzpatrick DR. Molecular pathobiology and immunology of malignant mesothelioma. *J Pathol* 1996;178:369-378.
47. Metintas M, Özdemir N, Solak M, et al. Chromosome analysis in pleural effusions. *Respiration* 1994; 61: 330 - 335.
48. Walker C, Everitt J, Barrett JC. Possible cellular and molecular mechanisms for asbestos carcinogenicity. *Am J Ind Med* 1992;21:253-273.
49. Craighead JE, Kane AB: The pathogenesis of malignant and nonmalignant serosal lesions in body cavities consequent to asbestos exposure. Jauren MC, Bignon J, eds. *Mesothelial cell and mesothelioma*. New York: Marcel Dekker, 1994:79-101.
50. Wagner JC. Historical background and perspectives of mesothelioma. In : Jaurand M-C, Bignon J, eds. *The mesothelial cell and mesothelioma*, New York : Marcel Dekker, 1994 : 1-15.
51. Jones JSP. Pathology of mesothelioma. *Eur Respir Rev* 1993; 3: 22-24.
52. Craighead JE. Current pathogenetic concepts of diffuse malignant mesothelioma. *Human Pathol* 1987; 18: 544-557.
53. Travis WD, Colby TV, Corrin B, et al. Histological typing of lung and pleural tumors. *International Histological Classification of Tumor*, 3ed. Springer, World Health Organisation 1999.
54. Umezu H, Kuwata K, Ebe Y et al. Microcystic variant of localized malignant mesothelioma accompanying an adenomatoid tumor-like lesion. *Pathology International*. 2002;52:416-422.
55. Galateau-Salle F. Well-differentiated papillary mesothelioma. Symposium 9-Pleural Lesions. *Histopathology* 2002; 41:154-156
56. Gelden TV, Hoogsteden HC, Vandenbroucke JP, et al. The influence of the diagnostic technique on the histopathological diagnosis in malignant mesothelioma. *Virchows Archiv A Pathol Anat* 1991; 418: 315-317.
57. Adams VI, Unni KK, Muhm JR, et al. Diffuse malignant pleural mesothelioma. diagnosis and survival in 92 cases. *Cancer* 1986; 58: 1540-1551.

58. Walz R, Koch HK. Malignant pleural mesothelioma: some aspects of epidemiology, differential diagnosis and prognosis. *Path Res Pract* 1990; 186: 124 - 134.
59. Metintaş M, Uçgun İ, Elbek O, et al. Computed tomography features in malignant pleural mesothelioma and other commonly seen pleural diseases. *Eur J Radiol* 2002; 41: 1-9.
60. Şahin AA, Çöplü L, Selçuk ZT, et al. Malignant pleural mesothelioma caused by environmental exposure to asbestos or erionite in rural Turkey: CT findings in 84 patients *AJR* 1993; 161: 533-537.
61. Senyigit A, Bayram H, Babayigit C, et al. Malignant pleural mesothelioma caused by environmental exposure to asbestos in the Southeast of Turkey: CT findings in 117 patients. *Respiration*. 2000;67:615-22.
62. Leung AN, Muller N, Miller RR. CT in differential diagnosis of diffuse pleural disease. *AJR* 1990;154:487-492.
63. Aberle DR, Balmes JR. Computed tomography of asbestos-related pulmonary parenchymal and pleural diseases. *Clin Chest Med* 1991;12:115-131.
64. Metintaş M, Özdemir N, Işıksoy S, et al. CT-guided pleural needle biopsy in the diagnosis of malignant mesothelioma. *J Comput Assist Tomogr* 1995; 19: 370-374.
65. McLoud TC. CT and MR in pleural disease. *Clin Chest Med* 1998;19:261-276.
66. Manzini VP, Brollo A, Bianchi C. Thrombocytosis in malignant pleural mesothelioma. *Tumori* 1990; 76: 576-578.
67. Bignon J. Overview of current issues with respect to mesothelioma. *Eur Respir Rev* 1993; 3: 12-17.
68. Rosai J. *Ackerman' s surgical pathology*, vol 1. 7^h ed. St. louis: Mosby, 1989: 266-277.
69. Alataş F, Alataş Ö, Metintaş M, et al. Diagostic value of CEA, CA 15-3, CA 19-9, Cyfra 21-1, NSE and TSA assay in pleural effusions. *Lung Cancer* 2001; 31: 9-16.
70. Butchart EG. Surgery of mesothelioma of the pleura. In: Roth JA, Ruckdeschel JC, Weisenburger TH, eds. *Thoracic oncology*. Philadelphia: Saunders, 1991: 566-573.
71. Vogelzang NJ. Maligant mesothelioma: diagnostic and management strategies in 1992. *Semin Oncol* 1992; 19 (Suppl) 11: 64-71.
72. Boutin C, Viallat JR, Rey F, Astoul PH. Clinical diagnosis of pleural mesothelioma. *Eur Respir Rev* 1993; 3: 18-21.
73. Boutin C, Rey F, Gouvernet J, et al. Thoracoscopy in pleural malignant mesothelioma. *Cancer* 1993; 72:394-404.
74. Law MR, Hodson ME, Heard BE. Malignant mesothelioma of the pleura: relation between histological type and clinical behaviour. *Thorax* 1982; 37: 810-815.
75. Beauchamp HD, Kundra NK, Aranson R, et al. The role of closed pleural needle biopsy in the diagnosis of malignant mesothelioma of the pleura. *Chest* 1992; 102: 1110-1112.
76. Boutin C, Rey F. Thoracoscopy in pleural malignant mesothelioma: a prospective study of 188 consecutive patients. Part I. Diagnosis. *Cancer* 1993;72: 389-393.
77. Roggli VL. Role of closed-needle biopsy in the diagnosis of malignant mesothelioma of the pleura (to the editor). *Chest* 1994; 105: 321-322.
78. Ordonez NG. Immunohistochemical diagnosis of epithelioid mesotheliomas: a critical review of old markers, new markers. *Hum Pathol* 2002; 33:953-967.

79. Ordonez NG. Value of TTF-1, E-Cadherin, B68, WT1 and CD44S immunostaining in distinguishing epithelial pleural mesothelioma from pulmonary and nonpulmonary adenocarcinoma. *Am J Surg Pathol* 2000; 24:598-606.
80. Ordonez NG. Immunohistochemistry of mesothelioma. *Am J Clin Pathol* 1999;112:75-89
81. King JE, Hasleton PS. Immunohistochemistry and diagnosis of malignant mesothelioma. *Histopathology* 2001; 38:471-476
82. Leers MPG, Aarts MMJ, Theunissen PHMH. E-cadherin and calretinin: a useful combination of immunohistochemical markers for differentiation between mesothelioma and metastatic adenocarcinoma. *Histopathology* 1998; 32:209-216.
83. Abutaily AS, Addis BJ, Roche WR. Immunohistochemistry in the distinction between malignant mesothelioma and pulmonary adenocarcinoma: a critical evaluation of new antibodies. *J Clin Pathol* 2002; 55:662-668.
84. Gibbs AR, Attanoos. Diffuse malignant mesotheliomas with heterologous differentiation. Symposium 9-pleural Lesions. *Histopathology* 2002; 41:156-158
85. Osborn M, Pelling N, Walker MM, et al. The value of 'mesothelium-associated' antibodies in distinguishing between metastatic renal cell carcinomas and mesotheliomas. *Histopathology* 2002; 41:301-307
86. Roggli V. Synovial sarcoma of the pleura: report of four cases. Symposium Pleural Lesions. *Histopathology* 2002; 41:147-149.
87. Cappello F, Barnes L. Synovial sarcoma and malignant mesothelioma of the pleura: review, differential diagnosis and possible role of apoptosis. *Pathology* 2001;33:142-148.
88. Rusch VW. International Mesothelioma Interest Group. A proposed new international TNM staging system for malignant pleural mesothelioma. *Chest* 1995;108:1122-1128.
89. Alberts AS, Falkson G, Goedhals L, et al. Malignant pleural mesothelioma: a disease unaffected by current therapeutic maneuvers. *J Clin Oncol* 1988; 6: 527-35.
90. Chailleux E, Dabouis G, Pioche D, et al. Prognostic factors in diffuse malignant pleural mesothelioma. *Chest* 1988; 93: 159-62.
91. Ruffie PA. Pleural mesothelioma. *Curr Opin Oncol* 1991; 3: 328-34.
92. Rusch VS, Ginsberg RJ. New concepts in the staging of mesotheliomas. In: Deslauriers J, Lacquet LK, eds. *International trends in general thoracic surgery*. St Louis: CV Mosby, 1990; 336-43.
93. Hillerdal G. Malignant mesothelioma 1982: review of 4,710 published cases. *Br J Dis Chest* 1983; 77: 321-43.
94. De Pangher MV, Brollo A, Franceschi S, et al. Prognostic factors of malignant mesothelioma of the pleura. *Cancer* 1993; 72: 410-17.
95. Herndon JE, Green MR, Chahinian P, et al. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the cancer and leukemia group B. *Chest* 1998;113:723-731.
96. Curran D, Sahnoud T, Therasse P, et al. Prognostic factors in patients with pleural mesothelioma: The European Organization for Research and Treatment of Cancer Experience. *J Clin Oncol* 1998; 16: 145-52.
97. Metintaş M, Metintaş S, Uçgun İ, et al. Prognostic factors in diffuse malignant pleural mesothelioma: effects of pretreatment clinical and laboratory characteristics. *Respir Med* 2001;95:829-835.

98. Baldini EH, Recht A, Strauss GM, et al. Patterns of failure after trimodality therapy for malignant pleural mesothelioma. *Ann Thorac Surg* 1997;63:334-338.
99. Sugarbaker DJ, Flores RM, Jaklitsch MT, et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. *J Thorac Cardiovasc Surg* 1999;117:54-65.
100. Sugarbaker DJ, Grondin SC. Techniques of pneumonectomy. Pleural pneumonectomy. *Chest Surg Clin N Am* 1999;9:379-392.
101. Hilaris BS, Nori D, Kwong E, et al. Pleurectomy and intraoperative brachytherapy and postoperative radiation in the treatment of malignant pleural mesothelioma. *Int J Radiat Oncol Biol Phys* 1984;10:325-331.
102. Martin-Ucar AE, Edwards JG, Rengajaran A, et al. Palliative surgical debulking in malignant mesothelioma. Predictors of survival and symptom control. *Eur J Cardiothorac Surg* 2001;20:1117-1121.
103. Achatzy R, Beba W, Ritschler R, et al. The diagnosis, therapy and prognosis of diffuse malignant mesothelioma. *Eur J Cardiothorac Surg* 1989;3:445-448.
104. Aziz T, Jilaihawi A, Prakash D. The management of malignant pleural mesothelioma; single centre experience in 10 years. *Eur J Cardiothorac Surg* 2002;22:298-305.
105. Soysal O, Karaoglanoglu N, Demiracan S, et al. Pleurectomy/decortication for palliation in malignant pleural mesothelioma: results of surgery. *Eur J Cardiothorac Surg* 1997;11:210-213.
106. Hasturk S, Tastede I, Unlu M, et al. Combined chemotherapy in pleurectomized malignant pleural mesothelioma patients. *J Chemother* 1996;8:159-164.
107. Maggi G, Casadio C, Cianci R, et al. Trimodality management of malignant pleural mesothelioma. *Eur J Cardiothorac Surg* 2001;19:346-350.
108. Rusch VW. Trials in malignant mesothelioma. *LCSG 851 and 882*. *Chest* 1994;106 (Suppl) 6:359S-362S.
109. DeLaria GA, Jensik R, Faber LP, Kittle CF. Surgical management of malignant mesothelioma. *Ann Thorac Surg* 1978;26:375-82.
110. Rusch VW, Rosenzweig K, Venkatraman E, et al. A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. *J Thorac Cardiovasc Surg* 2001;122:788-795.
111. Sugarbaker DJ, Norberto JJ, Swanson SJ. Surgical staging and work-up of patients with diffuse malignant pleural mesothelioma. *Semin Thorac Cardiovasc Surg* 1997;9:356-360.
112. Tomek S, Emri S, Krejcy K, Manegold C. Chemotherapy for malignant pleural mesothelioma: past results and recent developments. *Br J Cancer*. 2003;88:167-174.
113. Sterman DH, Kaiser LR, Albelda SM. Advances in the treatment of malignant pleural mesothelioma. *Chest* 1999;116:504-520.
- 114.
115. Antman KH, Pass HI, Schiff PB. Management of mesothelioma. In: Devita Jr VT, Hellman S, Rosenberg SA (eds). *Cancer: Principles and practise of oncology*. Philadelphia: Lippincott Williams and Wilkins. 2001:1943-1970
116. Kindler HL. Systemic therapy for malignant mesothelioma. In: Perry MC (ed). *American Society of Clinical Oncology 2002 Educational Book*. 2002;358-367.

117. Mattson K, Giaccone G, Kirkpatrick A, et al. Epirubicin in malignant mesothelioma: A phase II study of the EORTC Lung Cancer Cooperative Group. *J Clin Oncol* 1992;10:824-828.
118. Rusch VW, Figlin R. Pleural mesothelioma. In: Haksel CM (ed). *Cancer treatment*. W.B. Saunders Company. Philadelphia. 2001. 639-645.
119. Byrne MJ, Davidson JA, Musk AW, et al. Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study. *J Clin Oncol* 1999;17(1):25-30
120. Calvert AH, Hughes AN, Calvert PM, et al. Alimta in combination with carboplatin demonstrates clinical activity against malignant mesothelioma in phase I trial. *Proc Am Soc Clin Oncol* 2000(abstr 1936):19:495.
121. Boutin C, Nussbaum E, Monnet I, et al. Intrapleural treatment with gamma-interferon in early stage malignant pleural mesothelioma. *Cancer* 1994;74:2460-2467.
122. Astoul P, Picat-Joossen D, Viallat JR, Boutin C. Intrapleural administration of interleukin-2 for the treatment of patients with malignant pleural mesothelioma: a phase II study. *1998;83:2099-2104*
123. Metintas M, Özdemir N, Uçgun İ, et al. Cisplatin, mitomycin, and interferon alpha-2a combination chemimmunotherapy in the treatment of diffuse malignant pleural mesothelioma. *Chest* 1999;116:391-398.
124. Hunt KJ, Longton G, Williams MA, et al. Treatment of malignant mesothelioma with methotrexate and vinblastine, with or without platinum chemotherapy. *Chest* 1996;109:1239-1242.
125. Chahinian AP, Antman K, Goutsou M, et al. Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group. *Br J Clin Oncol* 1993;11:1559-1565.
126. Gordon W, Antman KH, Greenberger JS, et al. Radiation therapy in the management of patients with mesothelioma. *Int J Radiat Oncol Bio Phys* 1982;8:19-25.
127. Bissett D, Macbeth FR, Cram I. The role of palliative radiotherapy in malignant mesothelioma *Clin Oncol* 1991;3:315-317.
128. Davis SR, Tan L, Ball DL. Radiotherapy in the treatment of malignant mesothelioma of the pleura with special reference to its use in palliation. *Austral Radiol* 1994;38:212-214.
129. Sugarbaker DJ, Jaklitsch MT, Liptay MJ. Mesothelioma and radical multimodality therapy: who benefits? *Chest* 1995; 107: 345S -350S.
130. Sugarbaker DJ, Heher EC, Lee TH, et al. Extrapleural pneumonectomy, chemotherapy, and radiotherapy in the treatment of diffuse malignant pleural mesothelioma. *J Thorac Cardiovasc Surg* 1991;102:10-14.
131. Calvezos A, Koschel G, Husselmann H, et al. Malignant mesothelioma of the pleura: A prospective study of 132 patients from 1981-1985. *Klin Wochenschr* 1988;66: 607-613.
132. Rusch VW, Figlin R, Godwin D, et al. Intrapleural cisplatin and cytarabine in the management of malignant pleural effusions: a Lung Cancer Study Group Trial. *J Clin Oncol* 1991;9:313-319.
133. Rusch VW, Piantadosi S, Holmes EC. The role of extrapleural pneumonectomy in malignant pleural mesothelioma: a Lung Cancer Study Group Trial. *J Thorac Cardiovasc Surg* 1991; 102:1-9.
134. Smythe WR, Hwang HC, Amin KM, et al. Treatment of experimental human mesothelioma using adenovirus transfer of the herpes simplex-thymidine kinase gene. *Ann Surg* 1995; 222: 78-86.

135. Sandberg AA, Bridge J. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors. *Mesothelioma. Cancer Genet Cytogenet* 2001; 127: 93-110.
136. Masood R, Kundra A, Zhu S, Xia G, et al. Malignant mesothelioma growth inhibition by agents that target the VEGF and VEGF-C autocrine loops. *Int J Cancer* 2003; 104: 603-610.
137. Schouwink H, Ruevekamp M, Oppelaar H, et al. Photodynamic therapy for malignant mesothelioma: preclinical studies for optimization of treatment protocols. *Photochem Photobiol* 2001;73:410-417.
138. Pass HI, DELaney TF, Tochner Z, et al. Intrapleural photodynamic therapy: Results of phase I trial. *Ann surg Oncol* 1994; 1: 28-34.
139. Boutin C, Nussbaum E, Monnet I, et al. Intrapleural treatment with recombinant gamma-interferon in early stage malignant mesothelioma. *Cancer* 1994; 74: 2460-2467.
140. Monti G, Jaurand MC, Monnet I, et al: Intrapleural production of interleukin 6 during mesothelioma and its modulation by gamma-interferon treatment. *Cancer Res* 1994; 54: 4419-4423.
141. England DM, Hochholzer L, McCarthy MJ. Localized benign and malignant fibrous tumors of the pleura. *Am J Surg Pathol* 1989;13:640-658.
142. Skinetz C, Clarke R, Jacobs GH. Localized fibrous tumors of the pleura. *Pathol Res Pract* 1990;186:244-357.
143. Rusch VW. Diagnosis and treatment of pleural mesothelioma. *Semin Surg Oncol* 1990; 6: 279-285.
144. Pawade J, Du Boulay CEH, Herbert A. Malignant fibrous tumor of the pleura. *Eur Respir Rev* 1993;3:50-52.
145. Lee KS, Im J, Choe KO, et al. CT findings in benign fibrous mesothelioma of the pleura. *Am J Radiol* 1992;158:983-986.

EK KAYNAKLAR

1. Metintas M, Metintas S, Ak G, Erginel S, Alatas F, Kurt E, Ucgun I, Yildirim H. Metintas M, Metintas S, Ak G, et al. Epidemiology of pleural mesothelioma in a population with non-occupational asbestos exposure. *Respirology* 2008; 13: 117-121.
2. Batirel HF, Metintas M, Caglar HB, Yildizeli B, Lacin T, Bostanci K, Akgul AA, Evman S, Yuksel M. Trimodality Treatment of Malignant Pleural Mesothelioma. *J Thorac Oncol.* 2008;3: 499-504.
3. Metintas M, Ak G, Parspour S, Yildirim H, Erginel S, Alatas F, Batirel HF, Sivrikoz C, Metintas S, Dundar E. Local recurrence of tumor at sites of intervention in malignant pleural mesothelioma. *Lung Cancer* 2008; 61: 255-261.
4. Ak G, Metintas S, Metintas M, Yildirim H, Erginel S, Kurt E, Alatas F, Cadirci O. Prognostic factors according to the treatment schedule in malignant pleural mesothelioma. *J Thorac Oncol.* 2009; 4: 1425 -1430.
5. Yildirim H, Metintas M, Entok E, Ak G, Ak I, Dundar E, Erginel S. Clinical value of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiation of malignant mesothelioma from asbestos-related benign pleural disease: an observational pilot study. *J Thorac Oncol.* 2009 ; 4:1480-84.

6. Ak G, Metintas M, Metintas S, Yildirim H, Ozkan R, Ozden H. Three-dimensional evaluation of chemotherapy response in malignant pleural mesothelioma. *Eur J Radiol.* 2010; 74: 130-05.
7. Metintas M, Hillerdal G, Metintas S, Dumortier P. Endemic malignant mesothelioma: exposure to erionite is more important than genetic factors. *Arch Environ Occup Health* 2010; 65: 86-93.
8. Metintas M, Ak G, Dundar E, Yildirim H, Ozkan R, Kurt E, Erginel S, Alatas F, Metintas S. Medical thoracoscopy vs CT scan-guided Abrams pleural needle biopsy for diagnosis of patients with pleural effusions: a randomized, controlled trial. *Chest* 2010; 137: 1362-68.